Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Liabilities and Shareholders Equity (2020 - 2023)

Historic Liabilities and Shareholders Equity for Terns Pharmaceuticals (TERN) over the last 4 years, with Q3 2023 value amounting to $271.7 million.

  • Terns Pharmaceuticals' Liabilities and Shareholders Equity rose 4107.31% to $271.7 million in Q3 2023 from the same period last year, while for Dec 2023 it was $862.7 million, marking a year-over-year increase of 1043.7%. This contributed to the annual value of $287.0 million for FY2022, which is 7077.77% up from last year.
  • As of Q3 2023, Terns Pharmaceuticals' Liabilities and Shareholders Equity stood at $271.7 million, which was up 4107.31% from $289.7 million recorded in Q2 2023.
  • Over the past 5 years, Terns Pharmaceuticals' Liabilities and Shareholders Equity peaked at $301.3 million during Q1 2023, and registered a low of $92.3 million during Q4 2020.
  • Moreover, its 4-year median value for Liabilities and Shareholders Equity was $190.3 million (2021), whereas its average is $205.9 million.
  • In the last 5 years, Terns Pharmaceuticals' Liabilities and Shareholders Equity tumbled by 2294.97% in 2022 and then surged by 9998.41% in 2023.
  • Over the past 4 years, Terns Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $92.3 million in 2020, then soared by 82.11% to $168.1 million in 2021, then soared by 70.78% to $287.0 million in 2022, then fell by 5.34% to $271.7 million in 2023.
  • Its last three reported values are $271.7 million in Q3 2023, $289.7 million for Q2 2023, and $301.3 million during Q1 2023.